StockTrendNews.com

		US Markets in: hrs min sec

Set StockTrendNews.com as your Homepage! - Click Here

Home About Us Subscribe Contact

StockTrendNews (STN) Exclusive: Idera Pharmaceuticals, Inc

Enter Symbol or Keywords

StockDiagnostics.com Maintains a Suspended OPS Ranking on Idera Pharmaceuticals

Stock Quote: (NGM:IDRA)

11/17/2009

4.70

+0.04

+0.86%

20,332

StockDiagnostics.com Maintains a Suspended OPS Ranking on Idera Pharmaceuticals

Last

Price Change

% Chg

Volume

Sarasota, FL, November 17, 2009-StockDiagnostics.com has reiterated its suspended OPS Ranking for Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in its quarter ended September 30, 2009 because of its earli ... read full story

Website Address:	www.iderapharma.com
Industry:	Vaccine, Antibodies, Immunities

Most Recent STN Exclusives

02/09/2010

Cash Flow from Operations Improves 82% for News Corp.

02/09/2010

Revenue for Coach Increases by 3.25% even though Revenue for Apparel Industry Decreases by -22.4% over Latest 12 Months

02/09/2010

Free Cash Flow for News Corp. Reaches Two Year High

02/09/2010

Cash Flow from Operations Turns Positive for Siemens' First Quarter

02/09/2010

StockDiagnostics.com Has Issued a Cashless Earnings Warning For Energy XXI

02/08/2010

Second Quarter EBITDA Turns Positive for Harris

02/08/2010

Twelve Year High in EBITDA for Amazon.com

02/08/2010

Cash Flow from Operations for McCormick Reaches Fifteen Year High

02/08/2010

EBITDA for BMC Software Reaches Thirteen Year High

02/08/2010

EBITDA for CA Reaches Nine Year High

Interactive Chart: IDRA

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

More STN Exclusives for: IDRA

11/19/2009

Idera Pharmaceuticals' EBITDA Turns Positive for its Twelve Months

11/17/2009

Revenue for Idera Pharmaceuticals Increased by 36.71% over its most recent 12 months reports T12-NEWS

11/17/2009

Twelve Months Free Cash Flow Turns Negative for Idera Pharmaceuticals

... more IDRA exclusives

Other News Sources: IDRA

02/02/2010

Idera Pharmaceuticals to Present at Annual BIO CEO & Investor Conference 2010

01/28/2010

Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Intended for Autoimmune Disease Indications

01/19/2010

Idera Pharmaceuticals Announces Achievement of Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment

... more IDRA news from other sources

Daily Market Updates

02/09/2010

Markets Close Day After Strong Rally as Concerns Ease re Greece

Stocks closed today's strong rally following speculation that the European Union will step in to bail out Greece. Germany and its European Union partners are expected to offer Greece and other troubled EU members loan guarantees. Oil climbed almost $ ... read full story